tirzepatide going off market FDA confirms shortage is still over, gives compounders a grace period FDA Announces End To Compounded
Description
Primary Handling Editors: Ashley Castellanos-Jankiewicz and Sonia Muliyil, in collaboration with the Nature Medicine team
Stopping tirzepatide abruptly is not recommended without provider guidance
Side effects and safety profiles Every effective metabolic peptide comes with trade-offs
By improving insulin sensitivity and reducing inflammation, Mounjaro may alleviate PMS symptoms, menstrual cramps, and mood swings
